Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LCA-0061

Monoclonal antibody · Degrader of immunoglobulin E · developed by Lycia Therapeutics

Phase 1 Most advanced trial
LYCA Developer
1 Registered trials

What is LCA-0061?

LCA-0061 is an antibody-based therapeutic that selectively binds immunoglobulin E (IgE) and rapidly clears it through targeted degradation. It is being studied in atopic disease and peanut allergy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
immunoglobulin E
Mechanism
Degrader of immunoglobulin E
Pathways
targeted degradation of IgE
Therapy area
Immunology
Developer
Lycia Therapeutics, Inc. (LYCA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07701954 Phase 1 Atopic Disease Recruiting LYCA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic DiseasePeanut Allergies

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the LYCA page.

Follow LYCA, the company behind LCA-0061

See LYCA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LYCA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.